vTv Therapeutics (VTVT) Common Equity (2014 - 2026)

vTv Therapeutics has disclosed Common Equity across 13 years of filings, most recently posting $78.6 million for Q2 2026.

• In Q2 2026, Common Equity rose 3169.52% year-over-year to $78.6 million; the TTM figure through Jun 2026 stood at $78.6 million (up 3169.52% YoY), while the FY2025 annual figure was $64.4 million, up 350.58% from the prior year.
• Common Equity came in at $78.6 million for Q2 2026 at vTv Therapeutics, down from $90.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $90.0 million in Q1 2026 to a low of -$25.3 million in Q2 2023.
• Average Common Equity over 5 years is $14.2 million, with a median of $5.7 million recorded in 2025.
• Year-over-year, Common Equity plunged 196.54% in 2023 and soared 3169.52% in 2026.
• Over 5 years, Common Equity stood at -$10.7 million in 2022, then tumbled by 129.8% to -$24.7 million in 2023, then soared by 157.95% to $14.3 million in 2024, then soared by 350.58% to $64.4 million in 2025, then climbed by 22.03% to $78.6 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $78.6 million in Q2 2026, $90.0 million in Q1 2026, and $64.4 million in Q4 2025.